Subscribe
merck-be-well-logo-2
Copyright © 2009-2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All rights reserved.
21 September 2016Americas

Sanofi sues Merck over Lantus patents

Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus (insulin glargine injection) and Lantus SoloSTAR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More on this story

Americas
Sanofi takes on Mylan over diabetes injection
25 October 2017   Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility